{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Amirthalingam G"],"pubmed_abstract":["The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50-89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose intervals, and evaluate these against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. We show that antibody levels 14-35 days after dose two are higher in BNT162b2 recipients with an extended vaccine interval (65-84 days) compared with those vaccinated with a standard (19-29 days) interval. Following the extended schedule, antibody levels were 6-fold higher at 14-35 days post dose 2 for BNT162b2 than AZD1222. For both vaccines, VE was higher across all age-g"],"journal":["Nature communications"],"pagination":["7217"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8664823"],"repository":["biostudies-literature"],"pubmed_title":["Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England."],"pmcid":["PMC8664823"],"pubmed_authors":["Moss P","Ladhani SN","Tessier E","Bernal JL","Linley E","Warrener L","Stowe J","Baawuah F","O'Brien M","Whitaker H","Andrews NJ","Subbarao S","Whillock C","Brown KE","Ireland G","Ramsay ME","Amirthalingam G","Gower C"],"additional_accession":[]},"is_claimable":false,"name":"Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England.","description":"The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50-89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose intervals, and evaluate these against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. We show that antibody levels 14-35 days after dose two are higher in BNT162b2 recipients with an extended vaccine interval (65-84 days) compared with those vaccinated with a standard (19-29 days) interval. Following the extended schedule, antibody levels were 6-fold higher at 14-35 days post dose 2 for BNT162b2 than AZD1222. For both vaccines, VE was higher across all age-g","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-05T16:09:52.452Z","creation":"2025-04-05T16:09:52.452Z"},"accession":"S-EPMC8664823","cross_references":{"pubmed":["34893611"],"doi":["10.1038/s41467-021-27410-5"]}}